Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.

Vital, E M; Dass, S; Rawstron, A C; Buch, M H; Goëb, V; Henshaw, K; Ponchel, F; Emery, P

Vital, E M; Dass, S; Rawstron, A C; Buch, M H; Goëb, V; Henshaw, K; Ponchel, F; Emery, P.

Affiliation

Vital EM; University of Leeds, Chapel Allerton Hospital and Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.

Arthritis Rheum ; 62(5): 1273-9, 2010 May.

Article in En | MEDLINE | ID: mdl-20131284

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Arthritis, Rheumatoid/immunology; B-Lymphocytes/drug effects; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes/cytology; Drug Resistance; Flow Cytometry; Humans; Logistic Models; Lymphocyte Count; Middle Aged; Predictive Value of Tests; Retreatment; Rituximab; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / B-Lymphocytes / Antirheumatic Agents / Antibodies, Monoclonal Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Arthritis Rheum Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google